Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 2 respectively.
End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the erythropoietin (EPO) market are Amgen Inc., Johnson & Johnson, Roche Group, Pfizer Inc., Novartis, Celltrion Inc, and LG Life Sciences Ltd. The global erythropoietin (EPO) market is expected to grow from $0.96 billion in 2020 to $1.1 billion in 2021 at a compound annual growth rate (CAGR) of 14.6%. The growth is...
The global prevalence of CKD is estimated to be about 9% to 10%.Chronic Kidney Disease (CKD) is associated with poor outcomes, mainly due to the high burden of comorbidity. Along with rising aging population, increasing number of CKD patients are suffering from comorbidities such as hypertension, diabetes, heart failure, cancer, and...
The global hemodialysis market reached a value of US$ 80 Billion in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 4.8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87...
The global biologics market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different...
904 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Oct 2021
Endoscopy is a minimally invasive or non-invasive medical procedure that utilizes specialized devices like endoscopes for the detailed inspection or assessment, and manipulation or treatment of diseased organs or tissues by visualizing the internal organ or area of interest. The constantly advancing various emergency...
Chronic Kidney Disease market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Chronic Kidney Disease Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Chronic Kidney Disease types, applications. Further, Chronic...
120 pages •
By Infiniti Research Limited
• Aug 2021
Global Heparin Market 2021-2025 The analyst has been monitoring the heparin market and it is poised to grow by $ 2.29 bn during 2021-2025, progressing at a CAGR of about 6% during the forecast period. Our report on the heparin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges,...
Embolotherapy Market The global embolotherapy market value, which was $3,082.9 million in 2020, will likely reach $6,447.1 million in 2030, at a 7.7% CAGR between 2020 and 2030, according to the market research report published . The key factors driving the demand for embolotherapy procedures are: •...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.